Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 12/20 | 0.70 |
| ▸ | FPR3 | P25089 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23019685 | 1.00 | USP30 (0.70) | USP30FPR3FPR2RIPK1HDAC4 | |
| SCHEMBL18124204 | 1.00 | USP30 (0.70) | USP30FPR3FPR2RIPK1HDAC4 | |
| SCHEMBL28513485 | 0.88 | USP30 (0.67) | USP30RIPK1HDAC4HDAC6PARP1 | |
| SCHEMBL18124183 | 0.88 | USP30 (0.67) | USP30RIPK1HDAC4HDAC6PARP1 | |
| SCHEMBL29778997 | 0.88 | USP30 (0.67) | USP30RIPK1HDAC4HDAC6PARP1 | |
| SCHEMBL18115999 | 0.83 | USP30 (0.49) | USP30 | |
| SCHEMBL19990877 | 0.83 | USP30 (0.49) | USP30 | |
| SCHEMBL3720765 | 0.82 | USP30 (0.65) | USP30FPR3FPR2HDAC4HDAC6 | |
| SCHEMBL18124184 | 0.82 | USP30 (1.00) | USP30FPR3FPR2 | |
| SCHEMBL26187387 | 0.82 | USP30 (0.59) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885FPR3 4726/4885FPR2 4753/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | USP30 1/4885FPR3 3877/4885FPR2 4469/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885FPR3 4692/4885FPR2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.